Cancer Research Meeting Calendar  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 15-19, January 1, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kalmus, J.
Right arrow Articles by Vaupel, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Kalmus, J.
Right arrow Articles by Vaupel, P.

Dose-dependent Effects of Hydralazine on Microcirculatory Function and Hyperthermic Response of Murine FSall Tumors1

Joachim Kalmus, Paul Okunieff2 and Peter Vaupel

Department of Radiation Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114

The effects of the vasodilator hydralazine (HYD) on microcirculatory function and hyperthermic response were studied in early generation isotransplants of a spontaneous C3Hf/Sed mouse fibrosarcoma (FSall). Red blood cell flux (RBC flux) in superficial tumor regions was assessed using laser Doppler flowmetry. A differential microcirculatory response was seen between tumor and normal skin after 0.25 µg/g i.p. HYD, the tumor showing a transient increase in flow and the skin remaining almost stable. At 1.0 µg/g i.p., the differential response continued, this time with a transient fall in tumor blood flow but again no change in skin flow. High dose hydralazine (10.0 µg/g i.p.) was associated with a dramatic and prolonged decrease in tumor blood flow but a lesser and only transient decline in skin flow.

Identical doses of hydralazine were given 30 min prior to heat treatment (43.5°C for 15, 30, or 60 min). Tumor growth was measured daily and compared to controls (HT without hydralazine). Hydralazine at 0.25 µg/g i.p. did not affect heat induced growth delay. At 1.0 µg/g i.p., it significantly increased growth delay upon heat exposures of 15 min, but not after 30 or 60 min HT. Hydralazine at 10 µg/g i.p. increased growth delay for all heat doses (P < 0.05). Hydralazine alone had no influence on growth delay of sham-heated tumors. The results obtained clearly indicate that tumor and normal tissues have microcirculatory differences in the time-course, degree and/or direction of response after hydralazine, and that hydralazine has potential for increasing the response of tumor to HT.

1 This work was supported in part by NIH Grants CA48096 and CA13311, by the ACS Career Development Award, and by the Deutsche Forschungsgemeinschaft Postdoctoral Fellowship.

2 To whom requests for reprints should be addressed, at Department of Radiation Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114.

Received 1/30/89. Revised 5/18/89. Revised 9/26/89. Accepted 10/ 3/89.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.